Daiichi Sankyo, Inc. Europe is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin

DAIICHI SANKYO EUROPE GmbH has applied in 28 European countries for approval of a new antihypertensive medication. It is a fixed combination (CS-8663) of two substances, the angiotensin receptor blocker (ARB) Olmesartan and the calcium antagonist Amlodipin.